8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 18, 2024

CHEWY, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-38936	90-1020167
(State or Other Jurisdiction<br>of Incorporation)	(Commission File Number)	(IRS Employer<br>Identification No.)		7700 West Sunrise Boulevard, Plantation, Florida	33322
---	---
(Address of Principal Executive Offices)	(Zip Code)

(786) 320-7111

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange<br>on which registered
Class A Common Stock, par value $0.01 per share	CHWY	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 8.01 Other Events.

As previously announced on October 30, 2023, Chewy, Inc. (“Chewy” or the “Company”) entered into certain transactions (the “Transactions”) with affiliates of BC Partners Advisors LP pursuant to an Agreement and Plan of Merger. The Transactions resulted in, among other things, Chewy Pharmacy KY, LLC (“Chewy Pharmacy KY”) becoming an indirect wholly-owned subsidiary of the Company.

The Company is filing this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, which is incorporated herein by reference, solely to recast certain financial information to reflect the operations of Chewy Pharmacy KY as part of its consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended January 30, 2022 originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 29, 2022 (the “2021 Form 10-K”), the Company’s Annual Report on Form 10-K for the fiscal year ended January 29, 2023 originally filed with the SEC on March 22, 2023 (the “2022 Form 10-K”) and the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended April 30, 2023, July 30, 2023 and October 29, 2023 originally filed with the SEC on May 31, 2023, August 30, 2023 and December 6, 2023, respectively (collectively, the “2023 Form 10-Qs” and together with the 2021 Form 10-K and 2022 Form 10-K, the “Previous Reports”). The Company has also included in Exhibit 99.1 certain recasted non-GAAP financial measures which reflect the operations of Chewy Pharmacy KY. See “Non-GAAP Financial Measures” in Exhibit 99.1 to this Form 8-K for additional information.

The recasted financial information contained in Exhibit 99.1 to this Form 8-K does not represent a restatement of previously issued financial statements. This Form 8-K does not reflect other events occurring after the filing dates of the Previous Reports, except as otherwise reflected in Exhibit 99.1. This Form 8-K should be read in conjunction with the Previous Reports and the other SEC filings made by the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Recasted historical unaudited condensed consolidated financial information of the Company reflecting Chewy Pharmacy KY’s operations.
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CHEWY, INC.
Date:	January 18, 2024	By:	/s/ Stacy Bowman
			Stacy Bowman
			Interim Chief Financial Officer and Chief Accounting Officer

Document

Exhibit 99.1

CHEWY, INC.

SUPPLEMENTAL FINANCIAL INFORMATION

(Unaudited)

Overview

On October 30, 2023, Chewy, Inc. (“Chewy” or the “Company”) entered into certain transactions (the “Transactions”) with affiliates of BC Partners Advisors LP pursuant to an Agreement and Plan of Merger. The Transactions resulted in such affiliates restructuring their ownership interests in the Company and Chewy Pharmacy KY, LLC (“Chewy Pharmacy KY”) becoming an indirect wholly-owned subsidiary of the Company.

In this Exhibit 99.1, the Company has provided certain recast historical unaudited financial information prepared in accordance with GAAP reflecting the operations of Chewy Pharmacy KY as part of its consolidated financial statements, as well as certain non-GAAP financial measures reflecting the operations of Chewy Pharmacy KY. See “Non-GAAP Financial Measures” in Exhibit 99.1 to this Form 8-K for additional information.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

(in thousands, except share and per share data)

	As of
	October 29,<br>2023		October 29,<br>2023		Change
Assets	(As Filed)		(Restated)
Current assets:
Cash and cash equivalents	$	469,409	$	469,909
Marketable securities	487,772		487,772		—
Accounts receivable	160,980		161,405		425
Inventories	712,053		714,851		2,798
Prepaid expenses and other current assets	52,713		52,850		137
Total current assets	1,882,927		1,886,787		3,860
Property and equipment, net	514,701		514,795		94
Operating lease right-of-use assets	473,529		473,595		66
Goodwill	39,442		39,442		—
Other non-current assets	25,883		25,924		41
Total assets	$	2,936,482	$	2,940,543
Liabilities and stockholders’ equity
Current liabilities:
Trade accounts payable	$	1,078,429	$	1,081,939
Accrued expenses and other current liabilities	886,259		883,361		(2,898)
Total current liabilities	1,964,688		1,965,300		612
Operating lease liabilities	526,994		527,019		25
Other long-term liabilities	51,633		51,634		1
Total liabilities	2,543,315		2,543,953		638
Stockholders’ equity:
Preferred stock, $0.01 par value per share, 5,000,000 shares authorized, no shares issued and outstanding as of October 29, 2023	—		—		—
Class A common stock, $0.01 par value per share, 1,500,000,000 shares authorized, 119,950,022 shares issued and outstanding as of October 29, 2023	1,199		1,199		—
Class B common stock, $0.01 par value per share, 395,000,000 shares authorized, 311,188,356 shares issued and outstanding as of October 29, 2023	3,112		3,112		—
Additional paid-in capital	2,345,082		2,399,817		54,735
Accumulated deficit	(1,956,226)		(2,007,538)		(51,312)
Total stockholders’ equity	393,167		396,590		3,423
Total liabilities and stockholders’ equity	$	2,936,482	$	2,940,543

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

(in thousands, except share and per share data)

	As of
	July 30,<br>2023		July 30,<br>2023		Change
Assets	(As Filed)		(Restated)
Current assets:
Cash and cash equivalents	$	457,103	$	458,435
Marketable securities	448,323		448,323		—
Accounts receivable	162,681		164,456		1,775
Inventories	738,204		742,974		4,770
Prepaid expenses and other current assets	48,080		48,217		137
Total current assets	1,854,391		1,862,405		8,014
Property and equipment, net	511,755		511,866		111
Operating lease right-of-use assets	434,805		434,881		76
Goodwill	39,442		39,442		—
Other non-current assets	63,621		63,662		41
Total assets	$	2,904,014	$	2,912,256
Liabilities and stockholders’ equity
Current liabilities:
Trade accounts payable	$	1,119,316	$	1,123,629
Accrued expenses and other current liabilities	880,072		880,979		907
Total current liabilities	1,999,388		2,004,608		5,220
Operating lease liabilities	488,767		488,802		35
Other long-term liabilities	51,230		51,233		3
Total liabilities	2,539,385		2,544,643		5,258
Stockholders’ equity:
Preferred stock, $0.01 par value per share, 5,000,000 shares authorized, no shares issued and outstanding as of July 30, 2023	—		—		—
Class A common stock, $0.01 par value per share, 1,500,000,000 shares authorized, 118,530,123 shares issued and outstanding as of July 30, 2023	1,185		1,185		—
Class B common stock, $0.01 par value per share, 395,000,000 shares authorized, 311,188,356 shares issued and outstanding as of July 30, 2023	3,112		3,112		—
Additional paid-in capital	2,280,748		2,335,482		54,734
Accumulated deficit	(1,920,416)		(1,972,166)		(51,750)
Total stockholders’ equity	364,629		367,613		2,984
Total liabilities and stockholders’ equity	$	2,904,014	$	2,912,256

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

(in thousands, except share and per share data)

	As of
	April 30,<br>2023		April 30,<br>2023		Change
Assets	(As Filed)		(Restated)
Current assets:
Cash and cash equivalents	$	408,685	$	410,204
Marketable securities	394,487		394,487		—
Accounts receivable	151,719		152,776		1,057
Inventories	731,376		732,265		889
Prepaid expenses and other current assets	47,345		47,477		132
Total current assets	1,733,612		1,737,209		3,597
Property and equipment, net	474,764		474,890		126
Operating lease right-of-use assets	447,581		447,666		85
Goodwill	39,442		39,442		—
Other non-current assets	42,945		42,986		41
Total assets	$	2,738,344	$	2,742,193
Liabilities and stockholders’ equity
Current liabilities:
Trade accounts payable	$	1,113,849	$	1,115,269
Accrued expenses and other current liabilities	779,625		835,015		55,390
Total current liabilities	1,893,474		1,950,284		56,810
Operating lease liabilities	500,578		500,624		46
Other long-term liabilities	61,927		61,931		4
Total liabilities	2,455,979		2,512,839		56,860
Stockholders’ equity:
Preferred stock, $0.01 par value per share, 5,000,000 shares authorized, no shares issued and outstanding as of April 30, 2023	—		—		—
Class A common stock, $0.01 par value per share, 1,500,000,000 shares authorized, 115,919,876 shares issued and outstanding as of April 30, 2023	1,159		1,159		—
Class B common stock, $0.01 par value per share, 395,000,000 shares authorized, 311,188,356 shares issued and outstanding as of April 30, 2023	3,112		3,112		—
Additional paid-in capital	2,217,456		2,217,456		—
Accumulated deficit	(1,939,362)		(1,992,373)		(53,011)
Total stockholders’ equity	282,365		229,354		(53,011)
Total liabilities and stockholders’ equity	$	2,738,344	$	2,742,193

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

(in thousands, except share and per share data)

	As of
	January 29,<br>2023		January 29,<br>2023		Change
Assets	(As Filed)		(Restated)
Current assets:
Cash and cash equivalents	$	330,441	$	331,641
Marketable securities	346,944		346,944		—
Accounts receivable	126,349		126,969		620
Inventories	675,520		678,005		2,485
Prepaid expenses and other current assets	41,067		41,221		154
Total current assets	1,520,321		1,524,780		4,459
Property and equipment, net	478,738		478,885		147
Operating lease right-of-use assets	423,423		423,518		95
Goodwill	39,442		39,442		—
Other non-current assets	53,152		53,193		41
Total assets	$	2,515,076	$	2,519,818
Liabilities and stockholders’ equity
Current liabilities:
Trade accounts payable	$	1,030,882	$	1,033,184
Accrued expenses and other current liabilities	738,467		794,534		56,067
Total current liabilities	1,769,349		1,827,718		58,369
Operating lease liabilities	471,765		471,821		56
Other long-term liabilities	60,005		60,011		6
Total liabilities	2,301,119		2,359,550		58,431
Stockholders’ equity:
Preferred stock, $0.01 par value per share, 5,000,000 shares authorized, no shares issued and outstanding as of January 29, 2023	—		—		—
Class A common stock, $0.01 par value per share, 1,500,000,000 shares authorized, 114,160,531 shares issued and outstanding as of January 29, 2023	1,141		1,141		—
Class B common stock, $0.01 par value per share, 395,000,000 shares authorized, 311,188,356 shares issued and outstanding as of January 29, 2023	3,112		3,112		—
Additional paid-in capital	2,171,247		2,171,247		—
Accumulated deficit	(1,961,543)		(2,015,232)		(53,689)
Total stockholders’ equity	213,957		160,268		(53,689)
Total liabilities and stockholders’ equity	$	2,515,076	$	2,519,818

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

(in thousands, except share and per share data)

	As of
	January 30,<br>2022		January 30,<br>2022		Change
Assets	(As Filed)		(Restated)
Current assets:
Cash and cash equivalents	$	603,079	$	604,102
Accounts receivable	123,510		124,291		781
Inventories	560,430		562,744		2,314
Prepaid expenses and other current assets	36,513		34,028		(2,485)
Total current assets	1,323,532		1,325,165		1,633
Property and equipment, net	367,166		367,421		255
Operating lease right-of-use assets	372,693		372,707		14
Other non-current assets	22,890		22,930		40
Total assets	$	2,086,281	$	2,088,223
Liabilities and stockholders’ equity
Current liabilities:
Trade accounts payable	$	883,316	$	885,719
Accrued expenses and other current liabilities	761,563		815,444		53,881
Total current liabilities	1,644,879		1,701,163		56,284
Operating lease liabilities	410,168		410,168		—
Other long-term liabilities	16,498		16,512		14
Total liabilities	2,071,545		2,127,843		56,298
Stockholders’ equity:
Preferred stock, $0.01 par value per share, 5,000,000 shares authorized, no shares issued and outstanding as of January 30, 2022	—		—		—
Class A common stock, $0.01 par value per share, 1,500,000,000 shares authorized, 108,918,032 shares issued and outstanding as of January 30, 2022	1,089		1,089		—
Class B common stock, $0.01 par value per share, 395,000,000 shares authorized, 311,188,356 shares issued and outstanding as of January 30, 2022	3,112		3,112		—
Additional paid-in capital	2,021,310		2,021,310		—
Accumulated deficit	(2,010,775)		(2,065,131)		(54,356)
Total stockholders’ equity	14,736		(39,620)		(54,356)
Total liabilities and stockholders’ equity	$	2,086,281	$	2,088,223

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(in thousands, except per share data)

	13 Weeks Ended
	October 29,<br>2023		October 29,<br>2023		Change
	(As Filed)		(Restated)
Net sales	$	2,738,611	$	2,745,875
Cost of goods sold	1,957,850		1,964,019		6,169
Gross profit	780,761		781,856		1,095
Operating expenses:
Selling, general and administrative	611,718		612,375		657
Advertising and marketing	179,200		179,200		—
Total operating expenses	790,918		791,575		657
Loss from operations	(10,157)		(9,719)		438
Interest income, net	10,173		10,173		—
Other expense, net	(34,122)		(34,122)		—
Loss before income tax provision	(34,106)		(33,668)		438
Income tax provision	1,704		1,704		—
Net loss	$	(35,810)	$	(35,372)
Loss per share attributable to common Class A and Class B stockholders:
Basic	$	(0.08)	$	(0.08)
Diluted	$	(0.08)	$	(0.08)
Weighted-average common shares used in computing loss per share:
Basic	430,758		430,758		—
Diluted	430,758		430,758		—

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(in thousands, except per share data)

	13 Weeks Ended
	July 30,<br>2023		July 30,<br>2023		Change
	(As Filed)		(Restated)
Net sales	$	2,777,769	$	2,785,302
Cost of goods sold	1,990,996		1,996,581		5,585
Gross profit	786,773		788,721		1,948
Operating expenses:
Selling, general and administrative	619,202		619,889		687
Advertising and marketing	185,491		185,491		—
Total operating expenses	804,693		805,380		687
Loss from operations	(17,920)		(16,659)		1,261
Interest income, net	8,928		8,928		—
Other income, net	29,242		29,242		—
Income before income tax provision	20,250		21,511		1,261
Income tax provision	1,304		1,304		—
Net income	$	18,946	$	20,207
Earnings per share attributable to common Class A and Class B stockholders:
Basic	$	0.04	$	0.05
Diluted	$	0.04	$	0.05
Weighted-average common shares used in computing earnings per share:
Basic	428,618		428,618		—
Diluted	431,576		431,576		—

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(in thousands, except per share data)

	13 Weeks Ended
	April 30,<br>2023		April 30,<br>2023		Change
	(As Filed)		(Restated)
Net sales	$	2,784,675	$	2,790,639
Cost of goods sold	1,993,220		1,997,783		4,563
Gross profit	791,455		792,856		1,401
Operating expenses:
Selling, general and administrative	583,666		584,389		723
Advertising and marketing	183,733		183,733		—
Total operating expenses	767,399		768,122		723
Income from operations	24,056		24,734		678
Interest income, net	8,016		8,016		—
Other expense, net	(8,888)		(8,888)		—
Income before income tax provision	23,184		23,862		678
Income tax provision	1,003		1,003		—
Net income	$	22,181	$	22,859
Earnings per share attributable to common Class A and Class B stockholders:
Basic	$	0.05	$	0.05
Diluted	$	0.05	$	0.05
Weighted-average common shares used in computing earnings per share:
Basic	426,852		426,852		—
Diluted	430,471		430,471		—

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(in thousands, except per share data)

	52 Weeks Ended
	January 29,<br>2023		January 29,<br>2023		Change
	(As Filed)		(Restated)
Net sales	$	10,098,939	$	10,119,000
Cost of goods sold	7,268,034		7,284,505		16,471
Gross profit	2,830,905		2,834,495		3,590
Operating expenses:
Selling, general and administrative	2,125,766		2,128,688		2,922
Advertising and marketing	649,386		649,386		—
Total operating expenses	2,775,152		2,778,074		2,922
Income from operations	55,753		56,421		668
Interest income, net	9,291		9,290		(1)
Other expense, net	(13,166)		(13,166)		—
Income before income tax provision	51,878		52,545		667
Income tax provision	2,646		2,646		—
Net income	$	49,232	$	49,899
Earnings per share attributable to common Class A and Class B stockholders:
Basic	$	0.12	$	0.12
Diluted	$	0.12	$	0.12
Weighted-average common shares used in computing earnings per share:
Basic	422,331		422,331		—
Diluted	427,770		427,770		—

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(in thousands, except per share data)

	52 Weeks Ended
	January 30,<br>2022		January 30,<br>2022		Change
	(As Filed)		(Restated)
Net sales	$	8,890,773	$	8,967,407
Cost of goods sold	6,517,191		6,581,936		64,745
Gross profit	2,373,582		2,385,471		11,889
Operating expenses:
Selling, general and administrative	1,826,858		1,840,135		13,277
Advertising and marketing	618,902		618,902		—
Total operating expenses	2,445,760		2,459,037		13,277
Loss from operations	(72,178)		(73,566)		(1,388)
Interest expense, net	(1,639)		(1,641)		(2)
Loss before income tax provision	(73,817)		(75,207)		(1,390)
Income tax provision	—		—		—
Net loss	$	(73,817)	$	(75,207)
Loss per share attributable to common Class A and Class B stockholders:
Basic	$	(0.18)	$	(0.18)
Diluted	$	(0.18)	$	(0.18)
Weighted-average common shares used in computing loss per share:
Basic	417,218		417,218		—
Diluted	417,218		417,218		—

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands)

	39 Weeks Ended
	October 29,<br>2023		October 29,<br>2023		Change
	(As Filed)		(Restated)
Cash flows from operating activities
Net income	$	5,317	$	7,694
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	82,195		82,252		57
Share-based compensation expense	178,897		178,897		—
Non-cash lease expense	29,371		29,399		28
Change in fair value of equity warrants and investments	13,589		13,589		—
Other	3,810		3,810		—
Net change in operating assets and liabilities:
Accounts receivable	(34,631)		(34,436)		195
Inventories	(36,533)		(36,846)		(313)
Prepaid expenses and other current assets	(27,363)		(27,346)		17
Other non-current assets	(1,337)		(1,337)		—
Trade accounts payable	47,547		48,755		1,208
Accrued expenses and other current liabilities	144,599		140,374		(4,225)
Operating lease liabilities	(19,774)		(19,805)		(31)
Other long-term liabilities	1,669		1,664		(5)
Net cash provided by operating activities	387,356		386,664		(692)
Cash flows from investing activities
Capital expenditures	(110,898)		(110,902)		(4)
Cash paid for acquisition of business, net of cash acquired	(367)		(367)		—
Purchases of marketable securities	(876,189)		(876,189)		—
Proceeds from maturities of marketable securities	750,000		750,000		—
Net cash used in investing activities	(237,454)		(237,458)		(4)
Cash flows from financing activities
Payments for tax sharing agreement with related parties	(10,279)		(10,279)		—
Principal repayments of finance lease obligations	(475)		(479)		(4)
Payment of debt modification costs	(175)		(175)		—
Payments for tax withholdings related to vesting of share-based compensation awards	(5)		(5)		—
Net cash used in financing activities	(10,934)		(10,938)		(4)
Net increase in cash and cash equivalents	138,968		138,268		(700)
Cash and cash equivalents, as of beginning of period	330,441		331,641		1,200
Cash and cash equivalents, as of end of period	$	469,409	$	469,909

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands)

	26 Weeks Ended
	July 30,<br>2023		July 30,<br>2023		Change
	(As Filed)		(Restated)
Cash flows from operating activities
Net income	$	41,127	$	43,066
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	56,672		56,712		40
Share-based compensation expense	114,549		114,549		—
Non-cash lease expense	22,053		22,072		19
Change in fair value of equity warrants and investments	(20,244)		(20,244)		—
Other	793		793		—
Net change in operating assets and liabilities:
Accounts receivable	(36,332)		(37,487)		(1,155)
Inventories	(62,684)		(64,969)		(2,285)
Prepaid expenses and other current assets	(16,860)		(16,843)		17
Other non-current assets	(1,975)		(1,975)		—
Trade accounts payable	88,434		90,445		2,011
Accrued expenses and other current liabilities	131,796		131,374		(422)
Operating lease liabilities	(11,045)		(11,066)		(21)
Other long-term liabilities	864		860		(4)
Net cash provided by operating activities	307,148		307,287		139
Cash flows from investing activities
Capital expenditures	(79,213)		(79,217)		(4)
Cash paid for acquisition of business, net of cash acquired	(367)		(367)		—
Purchases of marketable securities	(442,769)		(442,769)		—
Proceeds from maturities of marketable securities	350,000		350,000		—
Net cash used in investing activities	(172,349)		(172,353)		(4)
Cash flows from financing activities
Payments for tax sharing agreement with related parties	(7,606)		(7,606)		—
Principal repayments of finance lease obligations	(351)		(354)		(3)
Payment of debt modification costs	(175)		(175)		—
Payments for tax withholdings related to vesting of share-based compensation awards	(5)		(5)		—
Net cash used in financing activities	(8,137)		(8,140)		(3)
Net increase in cash and cash equivalents	126,662		126,794		132
Cash and cash equivalents, as of beginning of period	330,441		331,641		1,200
Cash and cash equivalents, as of end of period	$	457,103	$	458,435

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands)

	13 Weeks Ended
	April 30,<br>2023		April 30,<br>2023		Change
	(As Filed)		(Restated)
Cash flows from operating activities
Net income	$	22,181	$	22,859
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	28,877		28,898		21
Share-based compensation expense	48,553		48,553		—
Non-cash lease expense	11,924		11,933		9
Change in fair value of equity warrants and investments	8,948		8,948		—
Other	489		489		—
Net change in operating assets and liabilities:
Accounts receivable	(25,370)		(25,807)		(437)
Inventories	(55,856)		(54,260)		1,596
Prepaid expenses and other current assets	(10,721)		(10,699)		22
Other non-current assets	298		298		—
Trade accounts payable	82,967		82,085		(882)
Accrued expenses and other current liabilities	39,399		38,724		(675)
Operating lease liabilities	(5,219)		(5,229)		(10)
Other long-term liabilities	1,922		1,920		(2)
Net cash provided by operating activities	148,392		148,712		320
Cash flows from investing activities
Capital expenditures	(21,573)		(21,573)		—
Cash paid for acquisition of business, net of cash acquired	(367)		(367)		—
Purchases of marketable securities	(394,098)		(394,098)		—
Proceeds from maturities of marketable securities	350,000		350,000		—
Net cash used in investing activities	(66,038)		(66,038)		—
Cash flows from financing activities
Payments for tax sharing agreement with related parties	(3,761)		(3,761)		—
Payment of debt modification costs	(175)		(175)		—
Principal repayments of finance lease obligations	(174)		(175)		(1)
Net cash used in financing activities	(4,110)		(4,111)		(1)
Net increase in cash and cash equivalents	78,244		78,563		319
Cash and cash equivalents, as of beginning of period	330,441		331,641		1,200
Cash and cash equivalents, as of end of period	$	408,685	$	410,204

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands)

	52 Weeks Ended
	January 29,<br>2023		January 29,<br>2023		Change
	(As Filed)		(Restated)
Cash flows from operating activities
Net income	$	49,232	$	49,899
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	83,307		83,440		133
Share-based compensation expense	158,122		158,122		—
Non-cash lease expense	39,470		39,389		(81)
Change in fair value of equity warrants	13,340		13,340		—
Other	1,069		1,072		3
Net change in operating assets and liabilities:
Accounts receivable	(2,735)		(2,573)		162
Inventories	(115,090)		(115,261)		(171)
Prepaid expenses and other current assets	(10,822)		(10,964)		(142)
Other non-current assets	1,114		1,114		—
Trade accounts payable	147,566		147,465		(101)
Accrued expenses and other current liabilities	8,245		7,932		(313)
Operating lease liabilities	(21,688)		(21,632)		56
Other long-term liabilities	(1,558)		(1,566)		(8)
Net cash provided by operating activities	349,572		349,777		205
Cash flows from investing activities
Capital expenditures	(230,290)		(230,310)		(20)
Cash paid for acquisition of business, net of cash acquired	(40,033)		(40,033)		—
Purchases of marketable securities	(543,761)		(543,761)		—
Proceeds from maturities of marketable securities	200,000		200,000		—
Other	(1,400)		(1,400)		—
Net cash used in investing activities	(615,484)		(615,504)		(20)
Cash flows from financing activities
Payments for tax sharing agreement with related parties	(2,828)		(2,828)		—
Payments for tax withholdings related to vesting of share-based compensation awards	(2,475)		(2,475)		—
Payment of debt modification costs	(750)		(750)		—
Principal repayments of finance lease obligations	(673)		(681)		(8)
Net cash used in financing activities	(6,726)		(6,734)		(8)
Net decrease in cash and cash equivalents	(272,638)		(272,461)		177
Cash and cash equivalents, as of beginning of period	603,079		604,102		1,023
Cash and cash equivalents, as of end of period	$	330,441	$	331,641
Supplemental disclosure of cash flow information
Cash paid for interest	$	2,057	$	2,058

All values are in US Dollars.

Exhibit 99.1

CHEWY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands)

	52 Weeks Ended
	January 30,<br>2022		January 30,<br>2022		Change
	(As Filed)		(Restated)
Cash flows from operating activities
Net loss	$	(73,817)	$	(75,207)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	55,009		55,319		310
Share-based compensation expense	77,772		77,772		—
Non-cash lease expense	32,958		32,996		38
Other	595		595		—
Net change in operating assets and liabilities:
Accounts receivable	(22,811)		(20,858)		1,953
Inventories	(47,126)		(41,745)		5,381
Prepaid expenses and other current assets	(18,931)		(7,357)		11,574
Other non-current assets	(4,960)		(4,960)		—
Trade accounts payable	104,951		84,058		(20,893)
Accrued expenses and other current liabilities	125,655		128,706		3,051
Operating lease liabilities	(19,850)		(19,864)		(14)
Other long-term liabilities	(17,706)		(17,712)		(6)
Net cash provided by operating activities	191,739		191,743		4
Cash flows from investing activities
Capital expenditures	(183,186)		(183,186)		—
Acquisition of assets	(10,086)		(10,086)		—
Net cash used in investing activities	(193,272)		(193,272)		—
Cash flows from financing activities
Proceeds from tax sharing agreement with related parties	43,714		43,714		—
Payment of debt modification and issuance costs	(1,584)		(1,584)		—
Principal repayments of finance lease obligations	(863)		(869)		(6)
Net cash provided by financing activities	41,267		41,261		(6)
Net increase in cash and cash equivalents	39,734		39,732		(2)
Cash and cash equivalents, as of beginning of period	563,345		564,370		1,025
Cash and cash equivalents, as of end of period	$	603,079	$	604,102
Supplemental disclosure of cash flow information
Cash paid for interest	$	2,051	$	2,053

All values are in US Dollars.

Exhibit 99.1

Non-GAAP Financial Measures

We have included in this Exhibit 99.1 certain measures of financial performance that are not prepared in accordance with GAAP (“non-GAAP”).

For each of these non-GAAP financial measures, we provide a reconciliation between the non-GAAP measure and the most directly comparable GAAP measure, an explanation of why management believes the non-GAAP measure provides useful information to financial statement users, and any additional purposes for which management uses the non-GAAP measure. This non-GAAP financial information is provided as additional information for the financial statement users and is not in accordance with, or an alternative to, GAAP. These non-GAAP financial measures may be different from non-GAAP financial measures used by other companies and may exclude items that are significant in understanding and assessing our financial results. Therefore, these financial measures should not be considered in isolation and relied upon as substitutes for analysis of our results as reported under GAAP.

Adjusted EBITDA and Adjusted EBITDA Margin

To provide investors with additional information regarding our financial results, we have disclosed in this Exhibit 99.1 adjusted EBITDA, a non-GAAP financial measure that we calculate as net income (loss) excluding depreciation and amortization; share-based compensation expense and related taxes; income tax provision; interest income (expense), net; transaction related costs; changes in the fair value of equity warrants; exit costs; and litigation matters and other items that we do not consider representative of our underlying operations. We have provided a reconciliation below of adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure.

We have included adjusted EBITDA and adjusted EBITDA margin in this Exhibit 99.1 because each is a key measure used by our management and board of directors to evaluate our operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA and adjusted EBITDA margin facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain variable charges. Accordingly, we believe that adjusted EBITDA and adjusted EBITDA margin provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

We believe it is useful to exclude non-cash charges, such as depreciation and amortization and share-based compensation expense from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision; interest income (expense), net; transaction related costs; changes in the fair value of equity warrants; exit costs; and litigation matters and other items which are not components of our core business operations. Adjusted EBITDA has limitations as a financial measure and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

•although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;

•adjusted EBITDA does not reflect share-based compensation and related taxes. Share-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy;

•adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;

•adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include changes in the fair value of equity warrants, exit costs, litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems; and

•other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces its usefulness as a comparative measure.

Because of these limitations, you should consider adjusted EBITDA and adjusted EBITDA margin alongside other financial performance measures, including various cash flow metrics, net income (loss), net margin, and our other GAAP results.

Exhibit 99.1

Adjusted Net Income (Loss) and Adjusted Basic and Diluted Earnings (Loss) per Share

To provide investors with additional information regarding our financial results, we have disclosed in this Exhibit 99.1 adjusted net income (loss) and adjusted basic and diluted earnings (loss) per share, which represent non-GAAP financial measures. We calculate adjusted net income (loss) as net income (loss) excluding share-based compensation expense and related taxes, changes in the fair value of equity warrants, and exit costs. We calculate adjusted basic and diluted earnings (loss) per share by dividing adjusted net income (loss) attributable to common stockholders by the weighted-average shares outstanding during the period. We have provided a reconciliation below of adjusted net income (loss) to net income (loss), the most directly comparable GAAP financial measure.

We have included adjusted net income (loss) and adjusted basic and diluted earnings (loss) per share in this Exhibit 99.1 because each is a key measure used by our management and board of directors to evaluate our operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted net income and adjusted basic and diluted earnings (loss) per share facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain variable gains and losses that do not represent a component of our core business operations. We believe it is useful to exclude non-cash share-based compensation expense and related taxes because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude exit costs and the changes in the fair value of equity warrants, because exit costs and the variability of equity warrant gains and losses are not representative of our underlying operations. Accordingly, we believe that these measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

Adjusted net income (loss) and adjusted basic and diluted earnings (loss) per share have limitations as financial measures and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP. Other companies may calculate adjusted net income (loss) and adjusted basic and diluted earnings (loss) per share differently, which reduces their usefulness as comparative measures. Because of these limitations, you should consider adjusted net income (loss) and adjusted basic and diluted earnings (loss) alongside other financial performance measures, including various cash flow metrics, net income (loss), basic and diluted earnings (loss) per share, and our other GAAP results.

Free Cash Flow

To provide investors with additional information regarding our financial results, we have also disclosed in this Exhibit 99.1 free cash flow, a non-GAAP financial measure that we calculate as net cash provided by (used in) operating activities less capital expenditures (which consist of purchases of property and equipment, capitalization of labor related to our website, mobile applications, and software development, and leasehold improvements). We have provided a reconciliation below of free cash flow to net cash provided by (used in) operating activities, the most directly comparable GAAP financial measure.

We have included free cash flow in this Exhibit 99.1 because it is used by our management and board of directors as an important indicator of our liquidity as it measures the amount of cash we generate. Accordingly, we believe that free cash flow provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

Free cash flow has limitations as a financial measure and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. There are limitations to using non-GAAP financial measures, including that other companies, including companies in our industry, may calculate free cash flow differently. Because of these limitations, you should consider free cash flow alongside other financial performance measures, including net cash provided by (used in) operating activities, capital expenditures and our other GAAP results.

Exhibit 99.1

(in thousands, except percentages)	13 Weeks Ended
Reconciliation of Net Loss to Adjusted EBITDA	October 29,<br>2023			October 29,<br>2023			Change
	(As Filed)			(Restated)
Net loss	$	(35,810)		$	(35,372)		$	438
Add (deduct):
Depreciation and amortization	25,523			25,540			17
Share-based compensation expense and related taxes	65,799			65,799			—
Interest income, net	(10,173)			(10,173)			—
Change in fair value of equity warrants	33,800			33,800			—
Income tax provision	1,704			1,704			—
Exit costs	(778)			(778)			—
Transaction related costs	1,041			1,041			—
Other	1,020			1,020			—
Adjusted EBITDA	$	82,126		$	82,581		$	455
Net sales	$	2,738,611		$	2,745,875		$	7,264
Net margin	(1.3)		%	(1.3)		%	—		%
Adjusted EBITDA margin	3.0		%	3.0		%	—		%		(in thousands, except per share data)	13 Weeks Ended
---	---	---	---	---	---	---
Reconciliation of Net Loss to Adjusted Net Income	October 29,<br>2023		October 29,<br>2023		Change
	(As Filed)		(Restated)
Net loss	$	(35,810)	$	(35,372)	$	438
Add (deduct):
Share-based compensation expense and related taxes	65,799		65,799		—
Change in fair value of equity warrants	33,800		33,800		—
Exit costs	(778)		(778)		—
Adjusted net income	$	63,011	$	63,449	$	438
Weighted-average common shares used in computing (loss) earnings per share and adjusted earnings per share:
Basic	430,758		430,758		—
Effect of dilutive share-based awards (1)	1,414		1,414		—
Diluted (1)	432,172		432,172		—
(Loss) earnings per share attributable to common Class A and Class B stockholders
Basic	$	(0.08)	$	(0.08)	$	—
Diluted (1)	$	(0.08)	$	(0.08)	$	—
Adjusted basic	$	0.15	$	0.15	$	—
Adjusted diluted (1)	$	0.15	$	0.15	$	—
(1) For the thirteen weeks ended October 29, 2023, our calculation of adjusted diluted earnings per share attributable to common Class A and Class B stockholders requires an adjustment to the weighted-average common shares used in the calculation to include the weighted-average dilutive effect of share-based awards.								(in thousands)	13 Weeks Ended
---	---	---	---	---	---	---
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow	October 29,<br>2023		October 29,<br>2023		Change
	(As Filed)		(Restated)
Net cash provided by operating activities	$	80,208	$	79,377	$	(831)
Deduct:
Capital expenditures	(31,685)		(31,685)		—
Free Cash Flow	$	48,523	$	47,692	$	(831)

Exhibit 99.1

(in thousands, except percentages)	13 Weeks Ended
Reconciliation of Net Income to Adjusted EBITDA	July 30,<br>2023			July 30,<br>2023			Change
	(As Filed)			(Restated)
Net income	$	18,946		$	20,207		$	1,261
Add (deduct):
Depreciation and amortization	27,795			27,814			19
Share-based compensation expense and related taxes	68,302			68,302			—
Interest income, net	(8,928)			(8,928)			—
Change in fair value of equity warrants	(29,192)			(29,192)			—
Income tax provision	1,304			1,304			—
Exit costs	5,260			5,260			—
Transaction related costs	2,126			2,126			—
Other	1,254			1,254			—
Adjusted EBITDA	$	86,867		$	88,147		$	1,280
Net sales	$	2,777,769		$	2,785,302		$	7,533
Net margin	0.7		%	0.7		%	—		%
Adjusted EBITDA margin	3.1		%	3.2		%	0.1		%		(in thousands, except per share data)	13 Weeks Ended
---	---	---	---	---	---	---
Reconciliation of Net Income to Adjusted Net Income	July 30,<br>2023		July 30,<br>2023		Change
	(As Filed)		(Restated)
Net income	$	18,946	$	20,207	$	1,261
Add (deduct):
Share-based compensation expense and related taxes	68,302		68,302		—
Change in fair value of equity warrants	(29,192)		(29,192)		—
Exit costs	5,260		5,260		—
Adjusted net income	$	63,316	$	64,577	$	1,261
Weighted-average common shares used in computing adjusted earnings per share:
Basic	428,618		428,618		—
Effect of dilutive share-based awards	2,958		2,958		—
Diluted	431,576		431,576		—
Earnings per share attributable to common Class A and Class B stockholders
Basic	$	0.04	$	0.05	$	0.01
Diluted	$	0.04	$	0.05	$	0.01
Adjusted basic	$	0.15	$	0.15	$	—
Adjusted diluted	$	0.15	$	0.15	$	—		(in thousands)	13 Weeks Ended
---	---	---	---	---	---	---
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow	July 30,<br>2023		July 30,<br>2023		Change
	(As Filed)		(Restated)
Net cash provided by operating activities	$	158,756	$	158,575	$	(181)
Deduct:
Capital expenditures	(57,640)		(57,644)		(4)
Free Cash Flow	$	101,116	$	100,931	$	(185)

Exhibit 99.1

(in thousands, except percentages)	13 Weeks Ended
Reconciliation of Net Income to Adjusted EBITDA	April 30,<br>2023			April 30,<br>2023			Change
	(As Filed)			(Restated)
Net income	$	22,181		$	22,859		$	678
Add (deduct):
Depreciation and amortization	28,877			28,898			21
Share-based compensation expense and related taxes	53,777			53,777			—
Interest income, net	(8,016)			(8,016)			—
Change in fair value of equity warrants	8,934			8,934			—
Income tax provision	1,003			1,003			—
Exit costs	2,357			2,357			—
Other	1,061			1,061			—
Adjusted EBITDA	$	110,174		$	110,873		$	699
Net sales	$	2,784,675		$	2,790,639		$	5,964
Net margin	0.8		%	0.8		%	—		%
Adjusted EBITDA margin	4.0		%	4.0		%	—		%		(in thousands, except per share data)	13 Weeks Ended
---	---	---	---	---	---	---
Reconciliation of Net Income to Adjusted Net Income	April 30,<br>2023		April 30,<br>2023		Change
	(As Filed)		(Restated)
Net income	$	22,181	$	22,859	$	678
Add:
Share-based compensation expense and related taxes	53,777		53,777		—
Change in fair value of equity warrants	8,934		8,934		—
Exit costs	2,357		2,357		—
Adjusted net income	$	87,249	$	87,927	$	678
Weighted-average common shares used in computing adjusted earnings per share:
Basic	426,852		426,852		—
Effect of dilutive share-based awards	3,619		3,619		—
Diluted	430,471		430,471		—
Earnings per share attributable to common Class A and Class B stockholders
Basic	$	0.05	$	0.05	$	—
Diluted	$	0.05	$	0.05	$	—
Adjusted basic	$	0.20	$	0.21	$	0.01
Adjusted diluted	$	0.20	$	0.20	$	—		(in thousands)	13 Weeks Ended
---	---	---	---	---	---	---
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow	April 30,<br>2023		April 30,<br>2023		Change
	(As Filed)		(Restated)
Net cash provided by operating activities	$	148,392	$	148,712	$	320
Deduct:
Capital expenditures	(21,573)		(21,573)		—
Free Cash Flow	$	126,819	$	127,139	$	320

Exhibit 99.1

(in thousands, except percentages)	52 Weeks Ended
Reconciliation of Net Income to Adjusted EBITDA	January 29,<br>2023			January 29,<br>2023			Change
	(As Filed)			(Restated)
Net income	$	49,232		$	49,899		$	667
Add (deduct):
Depreciation and amortization	83,307			83,440			133
Share-based compensation expense and related taxes	163,211			163,211			—
Interest income, net	(9,291)			(9,290)			1
Change in fair value of equity warrants	13,340			13,340			—
Income tax provision	2,646			2,646			—
Transaction related costs	3,953			3,953			—
Other	(460)			(460)			—
Adjusted EBITDA	$	305,938		$	306,739		$	801
Net sales	$	10,098,939		$	10,119,000		$	20,061
Net margin	0.5		%	0.5		%	—		%
Adjusted EBITDA margin	3.0		%	3.0		%	—		%		(in thousands, except per share data)	52 Weeks Ended
---	---	---	---	---	---	---
Reconciliation of Net Income to Adjusted Net Income	January 29,<br>2023		January 29,<br>2023		Change
	(As Filed)		(Restated)
Net income	$	49,232	$	49,899	$	667
Add:
Share-based compensation expense and related taxes	163,211		163,211		—
Change in fair value of equity warrants	13,340		13,340		—
Adjusted net income	$	225,783	$	226,450	$	667
Weighted-average common shares used in computing adjusted earnings per share:
Basic	422,331		422,331		—
Effect of dilutive share-based awards	5,439		5,439		—
Diluted	427,770		427,770		—
Earnings per share attributable to common Class A and Class B stockholders
Basic	$	0.12	$	0.12	$	—
Diluted	$	0.12	$	0.12	$	—
Adjusted basic	$	0.53	$	0.54	$	0.01
Adjusted diluted	$	0.53	$	0.53	$	—		(in thousands)	52 Weeks Ended
---	---	---	---	---	---	---
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow	January 29,<br>2023		January 29,<br>2023		Change
	(As Filed)		(Restated)
Net cash provided by operating activities	$	349,572	$	349,777	$	205
Deduct:
Capital expenditures	(230,290)		(230,310)		(20)
Free Cash Flow	$	119,282	$	119,467	$	185

Exhibit 99.1

($ in thousands, except percentages)	52 Weeks Ended
Reconciliation of Net Loss to Adjusted EBITDA	January 30,<br>2022			January 30,<br>2022			Change
	(As Filed)			(Restated)
Net loss	$	(73,817)		$	(75,207)		$	(1,390)
Add:
Depreciation and amortization	55,009			55,319			310
Share-based compensation expense and related taxes	85,308			85,308			—
Interest expense, net	1,639			1,641			2
Transaction related costs	2,423			2,423			—
Other	7,990			7,990			—
Adjusted EBITDA	$	78,552		$	77,474		$	(1,078)
Net sales	$	8,890,773		$	8,967,407		$	76,634
Net Margin	(0.8)		%	(0.8)		%	—		%
Adjusted EBITDA margin	0.9		%	0.9		%	—		%		(in thousands, except per share data)	52 Weeks Ended
---	---	---	---	---	---	---
Reconciliation of Net Loss to Adjusted Net Income	January 30,<br>2022		January 30,<br>2022		Change
	(As Filed)		(Restated)
Net loss	$	(73,817)	$	(75,207)	$	(1,390)
Add:
Share-based compensation expense and related taxes	85,308		85,308		—
Adjusted net income	$	11,491	$	10,101	$	(1,390)
Weighted-average common shares used in computing adjusted earnings (loss) per share:
Basic	417,218		417,218		—
Effect of dilutive share-based awards (1)	10,068		10,068		—
Diluted (1)	427,286		427,286		—
(Loss) earnings per share attributable to common Class A and Class B stockholders
Basic	$	(0.18)	$	(0.18)	$	—
Diluted (1)	$	(0.18)	$	(0.18)	$	—
Adjusted basic	$	0.03	$	0.02	$	(0.01)
Adjusted diluted (1)	$	0.03	$	0.02	$	(0.01)
(1) For the 52 weeks ended January 30, 2022, our calculation of adjusted diluted earnings per share attributable to common Class A and Class B stockholders requires an adjustment to the weighted-average common shares used in the calculation to include the weighted-average dilutive effect of share-based awards.								($ in thousands)	52 Weeks Ended
---	---	---	---	---	---	---
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow	January 30,<br>2022		January 30,<br>2022		Change
	(As Filed)		(Restated)
Net cash provided by operating activities	$	191,739	$	191,743	$	4
Deduct:
Capital expenditures	(183,186)		(183,186)		—
Free Cash Flow	$	8,553	$	8,557	$	4

23